中源协和：VUM03注射液是为满足临床局部使用需求而开发的通用现货型细胞制剂

Core Viewpoint - Zhongyuan Qihe (600645) has developed VUM03 injection for local clinical use, which is a general-purpose cell preparation expected to receive IND approval by March 2025 for treating non-active/mildly active Crohn's disease complex anal fistula [1] Group 1 - VUM03 injection is designed to meet local clinical usage needs [1] - The IND approval for VUM03 is anticipated in March 2025 [1] - The company will disclose any additional application projects in accordance with information disclosure rules [1]